• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies

tetano

Editor, Senior Moderator
Cell Rep Med


. 2024 May 15:101577.
doi: 10.1016/j.xcrm.2024.101577. Online ahead of print. Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies

Daniel J Sheward[SUP] 1 [/SUP], Pradeepa Pushparaj[SUP] 2 [/SUP], Hrishikesh Das[SUP] 3 [/SUP], Allison J Greaney[SUP] 4 [/SUP], Changil Kim[SUP] 2 [/SUP], Sungyong Kim[SUP] 2 [/SUP], Leo Hanke[SUP] 2 [/SUP], Erik Hyllner[SUP] 2 [/SUP], Robert Dyrdak[SUP] 2 [/SUP], Jimin Lee[SUP] 4 [/SUP], Xaquin Castro Dopico[SUP] 2 [/SUP], Pia Dosenovic[SUP] 2 [/SUP], Thomas P Peacock[SUP] 5 [/SUP], Gerald M McInerney[SUP] 2 [/SUP], Jan Albert[SUP] 2 [/SUP], Martin Corcoran[SUP] 2 [/SUP], Jesse D Bloom[SUP] 6 [/SUP], Ben Murrell[SUP] 7 [/SUP], Gunilla B Karlsson Hedestam[SUP] 8 [/SUP], B Martin Hällberg[SUP] 9 [/SUP]



Affiliations
Abstract

Descendants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant now account for almost all SARS-CoV-2 infections. The Omicron variant and its sublineages have spike glycoproteins that are highly diverged from the pandemic founder and first-generation vaccine strain, resulting in significant evasion from monoclonal antibody therapeutics and vaccines. Understanding how commonly elicited antibodies can broaden to cross-neutralize escape variants is crucial. We isolate IGHV3-53, using "public" monoclonal antibodies (mAbs) from an individual 7 months post infection with the ancestral virus and identify antibodies that exhibit potent and broad cross-neutralization, extending to the BA.1, BA.2, and BA.4/BA.5 sublineages of Omicron. Deep mutational scanning reveals these mAbs' high resistance to viral escape. Structural analysis via cryoelectron microscopy of a representative broadly neutralizing antibody, CAB-A17, in complex with the Omicron BA.1 spike highlights the structural underpinnings of this broad neutralization. By reintroducing somatic hypermutations into a germline-reverted CAB-A17, we delineate the role of affinity maturation in the development of cross-neutralization by a public class of antibodies.

Keywords: IGHV3-53; SARS-CoV-2; affinity maturation; cross neutralization; cryo-EM; germinal center; public antibodies; somatic hypermutation.

 
Back
Top Bottom